The ConcertAI Podcast

The Future of Drug Development: AI, RWD, and Regulatory Insights feat. Evidera's Ariel Berger

ConcertAI Season 3 Episode 2

In this episode of The ConcertAI Podcast, Jeff Elton, CEO of ConcertAI, engages with Ariel Berger, Executive Director of Integrated Solutions of Evidera, part of the PPD™ clinical research business of Thermo Fisher Scientific, to explore the innovative uses of real-world data (RWD) in regulatory settings, particularly in oncology. They discuss the critical role of RWD in shaping clinical trials and supporting regulatory decisions, emphasizing its growing importance in the regulatory approval process. The conversation also delves into the complexities of integrating AI and advanced data technologies to enhance trial designs and outcomes, highlighting how these tools are revolutionizing drug development efficiency and precision in patient care. Through insightful dialogue, the episode illuminates the transformative impact of these technologies on the future of healthcare and precision medicine.


Website
www.ConcertAI.com

LinkedIn
www.linkedin.com/company/concertai/

Twitter
www.twitter.com/concertai

People on this episode